BLISS BIOPHARMACEUTICAL (HANGZHOU)

Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (hereinafter referred to as "BlissBio"), founded in Qiantang Area, Hangzhou, Zhejiang Province in December 2017 by a number of American PhDs, is a clinical-stage national high-tech biopharmaceutical enterprise with independent intellectual properties that focuses on R&D and commercialization of anti-tumor macromolecular biotherapeutics. Since its foundation, guided by unmet clinical needs and based on rich experience accumulated in industrial R&D full life cycle of new medications, centering around multiple oncology indications, with continuous development and layout of gradient product pipeline of differentiated macromolecular biological innovative drugs, and through independent R&D and external cooperation as well, BlissBio has established and improved its multi-tech platforms, as well as independent capacity of production of antibody and ADC that meet international GMP standards. With "Together, We Improve Human Health" as the core value,..

Also known as: Bliss Biopharmaceutical (Hangzhou) Co., Ltd.

Primary location: Hangzhou China